Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

Dunn, E F; Iida, M; Myers, R A; Campbell, D A; Hintz, K A; Armstrong, E A; Li, C; Wheeler, D L

doi:10.1038/onc.2010.430

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib (BMS-354825, Sprycel), a potent, orally bioavailable inhibitor of several …